methyl 2-(3-oxocyclohexyl)phenylsulfonylacetate | 865705-21-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(3-oxocyclohexyl)phenylsulfonylacetate
• 英文别名: benzenesulfonyl-(3-oxo-cyclohexyl)-acetic acid methyl ester；methyl 2-(benzenesulfonyl)-2-(3-oxocyclohexyl)acetate
• CAS: 865705-21-1
• 化学式: C₁₅H₁₈O₅S
• 分子量: 310.371
• InChiKey: IUXWBTCDNSOHAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  85.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-(3-oxocyclohexyl)phenylsulfonylacetate 在 baker's yeast 、 sodium chloride 、 蔗糖 作用下， 以 二甲基亚砜 为溶剂， 反应 104.0h， 生成 (1R,3S)-3-[(phenylsulfonyl)methyl]cyclohaxanol
  参考文献：
  名称：

  Baker's yeast-mediated reduction of cyclohexanones containing a nitro or a sulfonyl group at C-3

  摘要：

  Baker's yeast-mediated reduction of 3-(nitromethyl)-, 3-(phenylsulfonyl)-, and 3-[(phenylsulfonyl)methyl]-cyclohexanone la,c,a led to the delivery of a hydride to the re-face of the prochiral ketones to provide cyclohexanols (1S,3S)- and (1S,3R)-2a,c,d with high enantioselectivities in good yields. The remote nitro and sulfonyl groups, in contrast to alkyl and sulfenyl groups, may play an important role in binding to an enzyme. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(97)00370-4
• 作为产物：
  描述：

  2-环己烯-1-酮 、 苯磺酰乙酸甲酯 在 三乙胺 作用下， 以 苯 为溶剂， 反应 8.0h， 以83%的产率得到methyl 2-(3-oxocyclohexyl)phenylsulfonylacetate
  参考文献：
  名称：

  Baker's yeast-mediated reduction of cyclohexanones containing a nitro or a sulfonyl group at C-3

  摘要：

  Baker's yeast-mediated reduction of 3-(nitromethyl)-, 3-(phenylsulfonyl)-, and 3-[(phenylsulfonyl)methyl]-cyclohexanone la,c,a led to the delivery of a hydride to the re-face of the prochiral ketones to provide cyclohexanols (1S,3S)- and (1S,3R)-2a,c,d with high enantioselectivities in good yields. The remote nitro and sulfonyl groups, in contrast to alkyl and sulfenyl groups, may play an important role in binding to an enzyme. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(97)00370-4

文献信息

• [EN] TETRAHYDROCARBAZOLES AND DERIVATIVES<br/>[FR] TETRAHYDROCARBAZOLES ET DERIVES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005092856A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRß agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在描述和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物对于治疗和预防由LXRα和/或LXRß激动剂调节的疾病是有用的，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇、高LDL-胆固醇、动脉粥样硬化疾病、糖尿病，特别是非胰岛素依赖型糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病如结肠炎、胰腺炎、肝胆瘀积/肝纤维化，以及具有炎症成分的疾病，如阿尔茨海默病或认知功能受损/可改善的疾病。
• Facile nucleophilic substitution of 3-tert-butyl-dimethylsilyloxyalk-2-enylphosphonium salts
  作者：Phil Ho Lee、Minkyoung Cho、In-Sup Han、Sunggak Kim

  DOI：10.1016/s0040-4039(99)01438-0

  日期：1999.9

  Phosphoniosilylation of α,β-enones with TBSOTf and triphenyl-phosphine at 0 °C affords 3-tert-butyldimethylsilyloxyalk-2-enylphosphonium salts, which undergo facile nucleophilic substitution with various nucleophiles to give 3-substituted silyl enol ethers in good yields.

  在0°C下用TBSOTf和三苯基膦进行膦酰基硅烷基化反应，得到3-叔丁基二甲基甲硅烷氧基烷-2-烯基phosph盐，该盐经过各种亲核试剂的容易亲核取代，从而以良好的收率得到了3-取代的甲硅烷基烯醇醚。
• Tetrahydrocarbazoles and derivatives
  申请人：Dehmlow Henrietta

  公开号：US20050215577A1

  公开（公告）日：2005-09-29

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 , n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在说明书和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物在LXRα和/或LXRβ激动剂调节的疾病的治疗和预防中有用，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇，高LDL-胆固醇，动脉粥样硬化疾病，糖尿病，特别是非胰岛素依赖性糖尿病，代谢综合征，脂质代谢异常，阿尔茨海默病，败血症，炎症性疾病，如结肠炎，胰腺炎，肝胆瘤/纤维化和具有炎症成分的疾病，如阿尔茨海默病或受损/可改善的认知功能。
• TETRAHYDROCARBAZOLES AND DERIVATIVES
  申请人：Dehmlow Henrietta

  公开号：US20100216833A1

  公开（公告）日：2010-08-26

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 , n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式（I）的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在说明书和权利要求书中定义，并且其药学上可接受的盐和/或药学上可接受的酯。该化合物用于治疗和预防LXRα和/或LXRβ激动剂调节的疾病，包括增加的脂质和胆固醇水平，特别是低HDL胆固醇，高LDL胆固醇，动脉粥样硬化疾病，糖尿病，特别是非胰岛素依赖性糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病，如结肠炎，胰腺炎，肝胆瘤/纤维化以及有炎症成分的疾病，例如阿尔茨海默病或受损/可改善的认知功能。
• US7906546B2
  申请人：——

  公开号：US7906546B2

  公开（公告）日：2011-03-15